HealthFriday, October 23, 20261 min read

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

By Ed Silverman · Via STAT Health · Published by Everything Blog

In short

The analysis reveals that only 31% of 97 cancer drugs approved by European regulators since 2017 have high clinical benefits, indicating a shift in innovation focus. Five drugmakers, with four based in China and Japan, dominate the top clinical benefit indications.

Key points

The analysis indicates a decrease in the proportion of cancer drugs with high clinical be…: The analysis indicates a decrease in the proportion of cancer drugs with high clinical benefits.
The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.: The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.
This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past…: This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past decade.

Sources checked by our analysis pipeline: 1

Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit and those that do were generated by a small number of drugmakers, mostly based in Asia, according to a new analysis.

Just 31% of 97 approved indications for 63 different cancer treatments offered a high clinical benefit and only nine of those medications received the top grade based on measurement tools used by the European Society for Medical Oncology. And of the 63 cancer drugs, just 19 were deemed to have at least one high-benefit indication.

Meanwhile, five drugmakers accounted for more than half of all 30 high-benefit indications for medicines approved by European regulators from January 2022 through July 2026. And four of those five companies are based in either China or Japan, which the researchers suggested is a “fundamental shift in the innovation ecosystem” over the past decade.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Original source: www.statnews.com

AI Analysis

Tone

Negative

In short

Key Points

The analysis indicates a decrease in the proportion of cancer drugs with high clinical be…: The analysis indicates a decrease in the proportion of cancer drugs with high clinical benefits.
The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.: The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.
This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past…: This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past decade.

Topics

Health

Was this summary useful?

AI Analysis

Tone

Negative

In short

Key Points

The analysis indicates a decrease in the proportion of cancer drugs with high clinical be…: The analysis indicates a decrease in the proportion of cancer drugs with high clinical benefits.
The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.: The dominance of Chinese and Japanese drugmakers in the top clinical benefit indications.
This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past…: This shift is attributed to a "fundamental shift in the innovation ecosystem" in the past decade.

Topics

Health

Was this summary useful?

STAT+: Diabetes association says ‘threat’ preceded members’ ejections but admits policies were unclear
The American Diabetes Association (ADA) has faced backlash after ejecting five members from its scientific session in New Orleans. Despite an apology and a review, members have protested through petitions and an 1,100-member boycott. The flagship journal has stopped accepting manuscripts and grant reviews, fundraisers, and educational activities have ceased. The ADA posted a news release about the review, which backs off from previous explanations, noting that the ADA’s code of conduct didn’t explicitly state that…
1 min read
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
A patient at Bristol Myers Squibb's early autoimmune CAR-T trial died following treatment, experiencing motor symptoms that did not improve despite standard treatments. The patient was given an immunosuppressant but developed septic pneumonia, leading to their death. This incident underscores safety concerns in CAR-T autoimmune trials and highlights the need for continued monitoring and improvement in treatment protocols.
1 min read
Celebrated Irish musician Dónal Lunny dies aged 79
Celebrated Irish musician Dónal Lunny, a founding member of three renowned bands and a pioneer of traditional Irish music, has passed away at the age of 79. Lunny, born in 1947, was a key figure in the revival and growth of Irish traditional music and was widely credited for leaving a lasting impact on the music scene in Ireland. Lunny's career was built on creativity, friendship, and collaboration, and he was presented with a lifetime achievement award at the BBC Radio 2 Folk Awards in 2018.
3 min read

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

In short

Key points

More in Health